FDA approves Synjardy (empagliflozin + metformin) to treat Type 2 Diabetes- Boehringer Ingelheim + Eli Lilly
The FDA has approved Synjardy (empagliflozin + metformin hydrochloride) tablets, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes (T2D). Synjardy is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin).
Synjardy is a combination of empagliflozin and metformin – two medicines with complementary mechanisms of action – to help control blood glucose in people with T2D. Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine.
Comment: Synjardy was also approved by the European Medicines Agency in May 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.